In the United States Court of Federal Claims 

OFFICE OF SPECIAL MASTERS

No. 17-487V

Filed: March 9, 2021

* * * * * * * * * * * * * * 

BARBARA PERKINS, *

* Dismissal; Tetanus-diphtheriaPetitioner, * acellular pertussis (“Tdap”) 

* Vaccine; Miller-Fisher Variant;

v. * Guillain-Barre Syndrome (“GBS”)

 *

SECRETARY OF HEALTH * 

AND HUMAN SERVICES, *

 *

 Respondent. *

* * * * * * * * * * * * * * 

Lawrence Michel, Esq., Kennedy, Berkley, et al., Salinas, KS, for petitioner.

Mallori Openchowski, Esq., U.S. Dept. of Justice, Washington, DC for respondent. 

DECISION1

Roth, Special Master:

On April 6, 2017, petitioner filed a petition for Vaccine Compensation in the National 

Vaccine Injury Compensation Program (“the Program”),

2

alleging that a tetanus-diphtheriaacellular pertussis (“Tdap”) she received on November 2, 2015 caused her to develop the MillerFisher variant of Guillain-Barre Syndrome (“GBS”). The information in the record, however, does 

not support entitlement to an award under the Program. On March 9, 2021, petitioner filed a 

Motion for Dismissal Decision requesting that her case be dismissed. ECF No. 66.

1 Although this Decision has been formally designated “unpublished,” it will nevertheless be posted on the 

Court of Federal Claims’ website, in accordance with the E-Government Act of 2002, Pub. L. No. 107-347, 

116 Stat. 2899, 2913 (codified as amended at 44 U.S.C. § 3501 note (2006)). This means the Decision will 

be available to anyone with access to the internet. However, the parties may object to the Decision’s 

inclusion of certain kinds of confidential information. Specifically, under Vaccine Rule 18(b), each party 

has fourteen days within which to request redaction “of any information furnished by that party: (1) that is 

a trade secret or commercial or financial in substance and is privileged or confidential; or (2) that includes 

medical files or similar files, the disclosure of which would constitute a clearly unwarranted invasion of 

privacy.” Vaccine Rule 18(b). Otherwise, the whole Decision will be available to the public. Id.

2 The Program comprises Part 2 of the National Childhood Vaccine Injury Act of 1986, Pub. L. No. 99-660, 

100 Stat. 3755, codified as amended, 42 U.S.C. §§ 300aa-10 et seq. (hereinafter “Vaccine Act” or “the 

Act”). Hereafter, individual section references will be to 42 U.S.C. § 300aa of the Act. 
2

To receive compensation under the Program, petitioner must prove either 1) that she 

suffered a “Table Injury” – i.e., an injury falling within the Vaccine Injury Table – corresponding 

to her vaccination, or 2) that she suffered an injury that was actually caused by a vaccine. See §§ 

13(a)(1)(A) and 11(c)(1). An examination of the record did not uncover any evidence that 

petitioner suffered a “Table Injury.” Because there were insufficient medical records supporting 

petitioner’s claim, petitioner was required to file a medical opinion to support her claim. See § 

13(a)(1).

Petitioner filed an expert report from Dr. Axelrod, an immunologist. See Pet. Ex. 12, ECF 

No. 24. In his initial report, Dr. Axelrod placed the onset of petitioner’s Miller Fisher variant of 

GBS one week prior to January 6, 2016. Pet. Ex. 12 at 2. He then later concluded that the onset of 

petitioner’s Miller Fisher variant of GBS was mid-December, or approximately 42 days after 

petitioner received the Tdap vaccination on November 2, 2015, based on the allegations contained

in the Petition. Id.; Petition at ¶ 3. In a subsequent report, Dr. Axelrod wrote that petitioner reported 

an onset of symptoms on December 15, 2015; however, Dr. Axelrod based this opinion on the 

information contained in petitioner’s affidavit which was filed on April 6, 2017, over a year after 

the events and which was not corroborated by any of the contemporaneous medical records. See 

Pet. Ex. 19, ECF No. 31; Pet. Ex. 8, ECF No. 10.

A Rule 5 status conference was held on December 19, 2018, at which time there was a 

discussion about the conflicts in onset between the contemporaneous medical records and the 

statements contained in petitioner’s affidavit which were relied upon by Dr. Axelrod in his report.

Scheduling Order at 3-4, ECF No. 37. Petitioner’s counsel advised that Dr. Axelrod could not 

support his opinion in this case unless onset was in mid-December. Id. Thereafter, petitioner filed 

a status report on February 4, 2019, confirming that Dr. Axelrod could only support a theory of 

causation if petitioner’s symptoms began in mid-December 2015. ECF No. 38. 

An onset hearing was held on November 5, 2019, to hear testimony from petitioner and her 

family members regarding the conflict between her alleged onset in mid-December 2015 and the 

onset reflected by her medical records. See Scheduling Order, ECF No. 52. A Ruling on Onset was 

issued on January 8, 2021, finding that the petitioner’s symptoms associated with her diagnosis of 

the Miller-Fisher variant of GBS began after January 4, 2016. ECF No. 60. As discussed in detail

in the Ruling on Onset, petitioner’s alleged onset of symptoms in mid-December 2015 found no 

support in the medical records, testimony, or other evidence submitted by petitioner. 

During a status conference on February 26, 2021, petitioner’s counsel advised that 

petitioner’s expert could not support a causation theory in this matter based on the onset found in 

the Ruling, and petitioner intended to file a Motion for Dismissal. See Scheduling Order at 1, ECF 

No. 64.

Accordingly, it is clear from the record in this case that petitioner has failed to demonstrate 

either that she suffered a “Table Injury” or that her injuries were “actually caused” by a 

vaccination. Thus, this case is dismissed for insufficient proof. The Clerk shall enter judgment 

accordingly.
3

IT IS SO ORDERED.

s/ Mindy Michaels Roth

 Mindy Michaels Roth

Special Master